| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 45.5 | 150.9 |
| Profit before tax | -29.6 | 21.2 |
| Net income | -29.6 | 21.6 |
| EPS (diluted, $ a share) | $-0.25 | $0.11 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -69.9% |
|---|---|
| Operating margin | -64.9% |
10-Q filed with the SEC, NASDAQ: ORGO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Organogenesis Holdings Inc.: key numbers
- Share price
- $0.8031Close, Nov 16
- Market cap
- $104M
- Shares outstanding
- 129.8MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Organogenesis Holdings Inc.
All →Organogenesis Holdings Financial Results
Organogenesis Holdings Inc. reported third quarter 2026 financial results, showing a significant 70% year-over-year revenue decline to $45.5 million. The company posted a net loss of $29.6 million as it navigates what management described as a 'market reset' in the advanced wound care sector. Despite the year-over-year drop, management noted sequential revenue growth and broad-based market share gains across its portfolio.
- Term
- 3 months
“We continue to strengthen our position as a leader in regenerative medicine as customers choose a partner and products they trust. Third quarter revenue increased sequentially, and our market share gains are broad-based across our portfolio. We are defining a sustainable future for advanced wound care as we emerge from the market reset a stronger company anchored by evidence-based living cell products that we believe will be the cornerstone of the market going forward.”
Gary S. Gillheeney, Sr., President, Chief Executive Officer and Chair of the Board